Eli Lilly Reports Superiority Results of Taltz (ixekizumab) in P-IV IXORA-R Study for Patients with Moderate to Severe Plaque Psoriasis

Shots:

• The P-IV IXORA-R study involves assessing of Taltz (160 mg at wk 0, followed by 80 mg at wks. 2, 4, 6, 8, 10, and 12, then 80 mg, q4w) vs Tremfya (SC, 100 mg) in 1,027 patients with moderate to severe plaque psoriasis evaluating efficacy, safety for 24 wks.
• The study met 1EPs @12 wks. demonstrating superiority in the proportion of patients achieving complete skin clearance by PASI 100. Additionally, @12wks. the study met all 2EPs including superiority in patients achieving PASI 75 @2wks., PASI 90 @4 & 8Wks., PASI 100 @4 & 8wks., and sPGA 0/50 @wks. 12 &1 respectively. Safety profile of Taltz was consistent with no new safety signals observed
•  Taltz is a mAb binds to interleukin 17A (IL-17A) cytokine and further inhibits its interaction with IL-17 receptor. Additionally, Lilly plans to share remaining @2EPs achieving PASI 100 at 24 weeks in 2020 

Click here to read full press release/ article | Ref: Eli Lilly | Image: Twitter